New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMelanotan II vs Chonluten

Melanotan II vs Chonluten

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Melanotan II
Anti-Aging & Longevity
Chonluten
Summary
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Half-Life
1–2 hours
Short (minutes for the peptide); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.25–0.5 mg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Promotes skin tanning and melanin production
  • Reduces UV exposure needed to tan
  • Enhances libido and sexual function
  • May suppress appetite
  • Faster, deeper tan development
  • Longer-lasting tan maintenance
  • Potential photoprotective effects
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
Side Effects
  • Nausea (very common, especially in first days)
  • Facial flushing
  • Spontaneous erections in men
  • Darkening or changes in existing moles (monitor closely)
  • +3 more
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
Stacks With